Private EquityScreenerRefer

MARKET INSIGHTS

  • EventsNEWPrivate market milestones
  • NewsPrecize daily pulse
  • BlogsIn-depth articles and opinions

GUIDES

Explore Now
  • Unlisted SharesStep-by-step · KYC
  • BuyingStep-by-step · KYC
  • SellingExit in 24 - 48 hours
  • Pre-IPOReturns · risks · case studies
  • Tax GuideBudget 2026 changes
  1. Home
  2. Unlisted share news
  3. Lords Mark Industries Ltd — Partners with C-MET to Develop AI-Powered B…

Lords Mark Industries Ltd — Partners with C-MET to Develop AI-Powered Breast Cancer Detection Device

10 Mar 2026

Add as preferred source
Key Takeaways

Key Takeaway:
Lords Mark Industries’ partnership with C-MET positions the company within the emerging AI-driven MedTech diagnostics space, focusing on scalable, radiation-free screening technology that could improve accessibility and early detection of breast cancer globally.

Key Takeaway:
Lords Mark Industries’ partnership with C-MET positions the company within the emerging AI-driven MedTech diagnostics space, focusing on scalable, radiation-free screening technology that could improve accessibility and early detection of breast cancer globally.

Lords Mark Industries

Lords Mark Industries

0.00%

Expert Analysis

Expert Analysis:

  • Lords Mark Industries Limited has signed a Technology Transfer Agreement (TTA) with the Centre for Materials for Electronic Technology (C-MET), an autonomous research organisation under the Ministry of Electronics and Information Technology (MeitY), to develop and commercialise an AI-powered, radiation-free wearable device for early breast cancer detection.

  • The proposed device integrates advanced thermal sensors with AI-driven temperature mapping, enabling non-invasive screening capable of detecting early-stage abnormalities without the radiation exposure associated with conventional mammography procedures.

  • The product is expected to be commercially launched by the end of the current calendar year, with the company aiming to deploy it for mass screening across India and global markets. The initiative targets the expanding breast cancer diagnostics market, projected to reach USD 12.88 billion by 2035.

Publisher:SCANX